Clinical performance of fecal syndecan 2/tissue factor pathway inhibitor 2 gene methylation assay in colorectal cancer screening

Zhang Tiao; Hao Yutong; Wen Haiyan; Liu Qijun

doi:10.13406/j.cnki.cyxb.003786

您当前的位置：

首页 >

文章列表页 >

Clinical performance of fecal syndecan 2/tissue factor pathway inhibitor 2 gene methylation assay in colorectal cancer screening

Clinical research | 更新时间：2025-10-22

- Clinical performance of fecal syndecan 2/tissue factor pathway inhibitor 2 gene methylation assay in colorectal cancer screening
- Journal of Chongqing Medical University Vol. 50, Issue 7, Pages: 983-987(2025)
- 作者机构：
  
  重庆国际旅行卫生保健中心/重庆海关口岸门诊部，重庆 401147
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003786
  CLC： R735.3
- Received：14 September 2024，
  
  Revised：2024-12-15，
  
  Accepted：25 December 2024，
  
  Published：28 July 2025
- 稿件说明：
移动端阅览
张朓,郝玉通,文海燕,等.粪便SDC2/TFPI2基因甲基化检测在结直肠癌筛查中的临床性能研究[J].重庆医科大学学报,2025,50(7):983-987.

Zhang Tiao,Hao Yutong,Wen Haiyan,et al.Clinical performance of fecal syndecan 2/tissue factor pathway inhibitor 2 gene methylation assay in colorectal cancer screening[J].Journal of Chongqing Medical University,2025,50(7):983-987.
张朓,郝玉通,文海燕,等.粪便SDC2/TFPI2基因甲基化检测在结直肠癌筛查中的临床性能研究[J].重庆医科大学学报,2025,50(7):983-987. DOI： 10.13406/j.cnki.cyxb.003786.

Zhang Tiao,Hao Yutong,Wen Haiyan,et al.Clinical performance of fecal syndecan 2/tissue factor pathway inhibitor 2 gene methylation assay in colorectal cancer screening[J].Journal of Chongqing Medical University,2025,50(7):983-987. DOI： 10.13406/j.cnki.cyxb.003786.

摘要

目的

探究粪便中蛋白聚糖2（syndecan 2，SDC2）和组织因子通路抑制物2（tissue factor pathway inhibitor 2，TFPI2）基因甲基化检测在结直肠癌前瞻性筛查中的临床性能。

方法

以常规体检的受试者作为研究对象，收集受试者的粪便样本并用SDC2和TFPI2基因甲基化试剂盒进行检测。试剂盒检测结果为阳性的受试者推荐其进行肠镜检查。

结果

1 215例受试者接受了粪便SDC2和TFPI2基因甲基化检测，包括708例男性和507例女性，平均年龄为（44.7±13.9）岁。其中有28例受试者的检测结果为阳性，阳性率为2.30%。阳性受试者接受肠镜检查的比例为96.43%（27/28），异常肠镜检查结果的比例为59.26%（16/27）。以肠镜和（或）病理检查作为诊断标准，该试剂盒对结直肠癌、进展期腺瘤和非进展期腺瘤的阳性预测值分别为7.41%、22.22%和7.41%。

结论

粪便SDC2和TFPI2基因甲基化检测在前瞻性的结直肠癌筛查中展示出良好的性能，为结直肠癌的筛查和辅助诊断提供了一种无创的方法。

Abstract

Objective

To investigate the clinical performance of fecal syndecan 2（SDC2）/tissue factor pathway inhibitor 2（TFPI2） gene methylation assay in prospective colorectal cancer screening.

Methods

The individuals who underwent routine physical examination were enrolled as subjects，and their fecal samples were collected and tested with fecal SDC2/TFPI2 gene methylation assay. In addition，enteroscopy was recommended for the subjects with positive results.

Results

A total of 1215 subjects received fecal SDC2/TFPI2 gene methylation assay，among whom there were 708 male subjects and 507 female subjects，with a mean age of （44.7±13.9） years. Among all subjects，28 had positive test results，resulting in a positive rate of 2.30%，and among these 28 subjects，27（96.43%） underwent enteroscopy，among whom 16（59.26%） had abnormal findings. With enteroscopy and/or pathological examination as diagnostic criteria，fecal SDC2/TFPI2 gene methylation assay had a positive predictive value of 7.41% for colorectal cancer，22.22% for progressive precancerous lesion，and 7.41% for non-progressive precancerous lesion.

Conclusion

Fecal SDC2/TFPI2 gene methylation assay shows good clinical performance in prospective colorectal cancer screening and thus provides a noninvasive method for the screening and auxiliary diagnosis of colorectal cancer.

关键词

Keywords

references

Sung H ， Ferlay J ， Siegel RL ， et al . Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2021 ， 71 （ 3 ）： 209 - 249 .

黄　庆，索彩霞，何　凤，等 . 结直肠癌的早期诊断策略和治疗进展 [J ] . 广州医药， 2024 ， 55 （ 1 ）： 1 - 8，53 .

Huang Q ， Suo CX ， He F ， et al . Early diagnostic strategies and therapeutic advances in colorectal cancer [J ] . Guangzhou Med J ， 2024 ， 55 （ 1 ）： 1 - 8，53 .

Shaukat A ， Levin TR . Current and future colorectal cancer screening strategies [J ] . Nat Rev Gastroenterol Hepatol ， 2022 ， 19 （ 8 ）： 521 - 531 .

Dekker E ， Tanis P J ， Vleugels JLA ， et al . Colorectal cancer [J ] . Lancet ， 2019 ， 394 （ 10207 ）: 1467 - 1480 .

Cronin KA ， Scott S ， Firth AU ， et al . Annual report to the nation on the status of cancer，part 1：National cancer statistics [J ] . Cancer ， 2022 ， 128 （ 24 ）： 4251 - 4284 .

Chen HD ， Li N ， Ren JS ， et al . Participation and yield of a population-based colorectal cancer screening programme in China [J ] . Gut ， 2019 ， 68 （ 8 ）： 1450 - 1457 .

Imperiale TF ， Ransohoff DF ， Itzkowitz SH ， et al . Multitarget stool DNA testing for colorectal-cancer screening [J ] . N Engl J Med ， 2014 ， 370 （ 14 ）： 1287 - 1297 .

Imperiale TF ， Porter K ， Zella J ， et al . Next-generation multitarget stool DNA test for colorectal cancer screening [J ] . N Engl J Med ， 2024 ， 390 （ 11 ）： 984 - 993 .

Zhang WS ， Yang CG ， Wang SY ， et al . SDC2 and TFPI2 methylation in stool samples as an integrated biomarker for early detection of colorectal cancer [J ] . Cancer Manag Res ， 2021 ， 13 ： 3601 - 3617 .

Wang ZX ， Shang J ， Zhang GN ， et al . Evaluating the clinical performance of a dual-target stool DNA test for colorectal cancer detection [J ] . J Mol Diagn ， 2022 ， 24 （ 2 ）： 131 - 143 .

Inadomi JM ， Vijan S ， Janz NK ， et al . Adherence to colorectal cancer screening：a randomized clinical trial of competing strategies [J ] . Arch Intern Med ， 2012 ， 172 （ 7 ）： 575 - 582 .

Nikanjam M ， Kato S ， Kurzrock R . Liquid biopsy：current technology and clinical applications [J ] . J Hematol Oncol ， 2022 ， 15 （ 1 ）： 131 .

Luo HY ， Wei W ， Ye ZY ， et al . Liquid biopsy of methylation biomarkers in cell-free DNA [J ] . Trends Mol Med ， 2021 ， 27 （ 5 ）： 482 - 500 .

Porcaro F ， Voccola S ， Cardinale G ， et al . DNA methylation biomarkers in stool samples：enhancing colorectal cancer screening strategies [J ] . Oncol Rev ， 2024 ， 18 ： 1408529 .

Zhao FQ ， Bai P ， Xu JF ， et al . Efficacy of cell-free DNA methylation-based blood test for colorectal cancer screening in high-risk population：a prospective cohort study [J ] . Mol Cancer ， 2023 ， 22 （ 1 ）： 157 .

Oh TJ ， Oh HI ， Seo YY ， et al . Feasibility of quantifying SDC2 methylation in stool DNA for early detection of colorectal cancer [J ] . Clin Epigenetics ， 2017 ， 9 ： 126 .

Glöckner SC ， Dhir M ， Yi JM ， et al . Methylation of TFPI2 in stool DNA：a potential novel biomarker for the detection of colorectal cancer [J ] . Cancer Res ， 2009 ， 69 （ 11 ）： 4691 - 4699 .

储梦真，唐宜桂，张　敏，等 . SDC2和TFPI2基因甲基化联合检测在结直肠癌早期筛查中的应用价值 [J ] . 安徽医科大学学报， 2023 ， 9 （ 4 ）： 682 - 686 .

Chu MZ ， Tang YG ， Zhang M ， et al . The value of combined SDC2 and TFPI2 gene methylation testing in the early screening of colorecta l cancer [J ] . Acta Univ Med Anhui ， 2023 ， 9 （ 4 ）： 682 - 686 .

Liu S ， Wang Y ， Zhuo D ， et al . 564P A large-scale real-world study for colorectal cancer screening [J ] . Ann Oncol ， 2023 ， 34 ： S418 .

Li QZ ， Jiang WC ， Zhang YY ， et al . Methylation of Septin9，SRSF1，and PAX8 in early screening of colorectal cancer in the population undergoing physical examinations [J ] . Clin Lab ， 2023 ， 69 （ 12 ）： 1189 - 1203 .

Siegel R ， Miller KD ， Wagle NS ， et al . Cancer statistics，2023 [J ] . CA Cancer J Clin ， 2023 ， 73 ： 17 - 48 .

（责任编辑：周一青）

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Application of radiological indicators combined with the methylation of HOXA7 and SOX17 in plasma circulating tumor DNA in the early diagnosis of lung cancer

Potential value of miR-200a-3p as a biomarker for the diagnosis and prognosis of colorectal cancer

Identification of shared genetic features and molecular mechanisms of metabolic syndrome and colorectal cancer based on transcriptomic data

Association of antibiotics with tumor metastasis in colorectal cancer patients undergoing 5-fluorouracil treatment

Related Author

Zhang Tiao

Hao Yutong

Wen Haiyan

Liu Qijun

Liu Baojing

Wu Man

Feng Feixue

Zhang Yuxin

Related Institution

Department of Health Management，Chongqing International Travel Healthcare Center（Outpatient Department of Chongqing Customs Port）

School of Medical Technology，Shaanxi University of Chinese Medicine

Department of Laboratory Medicine， The Affiliated Hospital of Shaanxi University of Chinese Medicine

Department of Hematology and Oncology，Changsha First Hospital & Changsha Hospital Affiliated to Xiangya School of Medicine，Central South University

Department of Gynecology，Changsha First Hospital & Changsha Hospital Affiliated to Xiangya School of Medicine，Central South University

⁰